189 related articles for article (PubMed ID: 23678600)
1. [Aripiprazole as "dopamine sensitivity stabilizer"].
Tadokoro S
Nihon Rinsho; 2013 Apr; 71(4):684-8. PubMed ID: 23678600
[TBL] [Abstract][Full Text] [Related]
2. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
3. [Aripiprazole: a new atypical antipsychotic drug].
Fischer B; Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
Crismon ML; DeLeon A; Miller AL
Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
[No Abstract] [Full Text] [Related]
5. Agitation associated with aripiprazole initiation.
Lea JW; Stoner SC; Lafollette J
Pharmacotherapy; 2007 Sep; 27(9):1339-42. PubMed ID: 17723088
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Keck PE; McElroy SL
Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole: pharmacology, efficacy, safety and tolerability.
Kinghorn WA; McEvoy JP
Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole in the treatment of Alzheimer's disease.
De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
[TBL] [Abstract][Full Text] [Related]
11. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
Costentin J
Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
[TBL] [Abstract][Full Text] [Related]
12. Dopamine partial agonists: a new class of antipsychotic.
Lieberman JA
CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
[TBL] [Abstract][Full Text] [Related]
13. [A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Kerpel-Fronius S; Lóránt M
Neuropsychopharmacol Hung; 2004 Dec; 6(4):177-84. PubMed ID: 15825673
[TBL] [Abstract][Full Text] [Related]
14. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
15. Focus on aripiprazole.
Green B
Curr Med Res Opin; 2004; 20(2):207-13. PubMed ID: 15006016
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Leite JV; Guimarães FS; Moreira FA
Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
[TBL] [Abstract][Full Text] [Related]
17. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
Narita M; Takei D; Shiokawa M; Tsurukawa Y; Matsushima Y; Nakamura A; Takagi S; Asato M; Ikegami D; Narita M; Amano T; Niikura K; Hashimoto K; Kuzumaki N; Suzuki T
Eur J Pharmacol; 2008 Dec; 600(1-3):105-9. PubMed ID: 18955042
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
Strange PG
Trends Pharmacol Sci; 2008 Jun; 29(6):314-21. PubMed ID: 18471899
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole (Otsuka Pharmaceutical Co).
Ozdemir V; Fourie J; Ozdener F
Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
